Fludarabin Ebewe

Fludarabin Ebewe

fludarabine

Manufacturer:

Sandoz

Distributor:

Zuellig
Concise Prescribing Info
Contents
Fludarabine phosphate
Indications/Uses
Chronic lymphocytic leukemia (CLL) of B-cell type w/ sufficient bone marrow function. 1st- or 2nd-line treatment of sufficient bone marrow function. 1st-line treatment in later stages (RaI III/IV, Binet C) or in earlier stages if disease-related symptoms make treatment desirable.
Dosage/Direction for Use
Adult 25 mg/m2/day IV for 5 days every 28 days.
Contraindications
Hypersensitivity. Renal impairment & CrCl <30 mL/min; decompensated haemolytic anaemia. Pregnancy & lactation.
Special Precautions
Monitor signs of neurological side effects, haematological & non-haematological toxicity or autoimmune haemolytic anaemia. Renal & hepatic impairment. AML patients. Discontinue in case of haemolysis. Childn.
Adverse Reactions
Myelosuppression (neutropaenia, thrombocytopaenia, anaemia), pneumonia, fever, nausea, vomiting & diarrhoea. Fatigue, weakness, stomatitis, malaise, anorexia, oedema, chills, peripheral neuropathy, visual disturbances & skin rashes.
Drug Interactions
Combination w/ pentostatin is not recommended. Efficacy may be reduced by dipyridamole & other inhibitors of adenosine uptake. AraC.
ATC Classification
L01BB05 - fludarabine ; Belongs to the class of antimetabolites, purine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Fludarabin Ebewe inj 50 mg/2 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in